All In Biotech

Drug Trial Radar · NCT01403116

Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

Phase 3, Active-Controlled, Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

Last checked: Nov 19, 2026Latest source record: Aug 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 325 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

325

Actual

Start

Jul 2011

Primary completion

Sep 2013

Study completion Sep 2013

Sponsor

Lead sponsor
Clarus Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
PharmaNet; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
First posted
Jul 27, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and efficacy of an oral testosterone undecanoate formulation for use as testosterone-replacement therapy in men with low testosterone.

Conditions

  • Male Hypogonadism

Interventions

  • Oral testosterone undecanoateDrug

    Starting dose: 200 mg T (as TU) BID. Doses may be titrated up to a maximum dose of 300 mg T (as TU) BID or down to a minimum dose of 100 mg T (as TU) BID based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.

  • topical testosterone gelDrug

    Starting dose: 5 g T applied once daily. Doses may be titrated up to a maximum dose of 10 g daily or down to a minimum dose of 2.5 g daily based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Treated Patients With Average Serum Testosterone (T) Concentrations (Cavg) Between 300 and 1000 ng/dLTime frame: Following 90 days of treatment

Locations

30 sites in 2 countries. Site status is shown where the registry gives one.

  • Alabama Clinical Therapeutics, Inc.

    Birmingham, Alabama

  • Alabama Internal Medicine, PC

    Birmingham, Alabama

  • Alabama Clinical Therapeutics

    Calera, Alabama

  • Medical Affliated Research Center, Inc.

    Huntsville, Alabama

  • Quality of Life Medical and Research Centers, LLC

    Tucson, Arizona

  • Providence Clinical Research

    Burbank, California

  • South Orange County Endocrinology

    Laguna Hills, California

  • Tower Urology

    Los Angeles, California

  • David Geffen School of Medicine

    Los Angeles, California

  • Harbor-UCLA Medical Center, LA Biomedical Research Institute

    Torrance, California

  • Connecticut Clinical Research Center/ConnecTrials

    Middlebury, Connecticut

  • University of CT School of Medicine

    New Haven, Connecticut

  • South Florida Medical Research

    Aventura, Florida

  • University of Louisville

    Louisville, Kentucky

  • Johns Hopkins University

    Baltimore, Maryland

  • Boston University School of Medicine

    Boston, Massachusetts

  • Maimonides Medical Center

    Brooklyn, New York

  • Bruce R. Gilbert, MD, PhD

    Great Neck, New York

  • University Urology Associates

    New York, New York

  • Michael A. Werner, MD, PC

    Purchase, New York

  • Sunstone Medical Research

    Medford, Oregon

  • Urologic Consultants of Southeast Pennsylvania

    Bala-Cynwyd, Pennsylvania

  • Research Across America

    Carrollton, Texas

  • Research Across America

    Dallas, Texas

  • University of Washington

    Seattle, Washington

  • University of Bonn, Clinic for Dermatology and Allergy

    Bonn, Germany

  • University of Halle, Center for Reproduction and Androlgoy

    Halle, Germany

  • Praxis Dr. Szymula

    Leipzig, Germany

  • Praxis Dr. Schulze

    Markkleeberg, Germany

  • University of Muenster, Center for Reproduction and Andrology

    Münster, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.